Techniclone (TCLN) Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Techniclone (TCLN)

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: EZLibra who wrote (2418)	8/20/1998 7:40:00 PM
From: EZLibra	of 3702

All the hullaballoo over the proxy will blow over one way or the other and the markets and potential markets will still be available, in fact will be primed for the picking. CLTR is a virtual company, virtually cash and not much else. If they get through Idec (rituxan & Y2B8) they have to compete with Oncolym. It doesn't fool Mother Nature to wipe out the immune system as both of these CD20 ab's do. However, Idec has Genentech/Hoffman LaRoche backing them and they are formidable. Formidable as in sales force, not necessarily as in an extraordinarily efficacious treatment for low grade NHL. The results are finally available. Lym-1 has never come close to underperforming rituxan in low grade, read for yourselves.... biz.yahoo.com I think the Oncolym trial results will absolutely surprise and shock people, to the upside of course. It's too hot to be on the back burner. BTW, I also would like the options repriced to original strikes (exception the new guys), or the respective amounts reduced to comparable $. I am trying to speak to CEO about this. I think once again they counted their chix before they hatched. Better sooner than later (to quote WJC) because I think the TNT juggernaut is about to leave the station. Onward and upward!

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next